Last updated: 2026-10-05 21:19:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Heartbeam, Inc. (BEAT) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $0,67, with a market capitalization of $24,49M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,36 to $4,00. This page covers its latest market performance, valuation, price trends and company information.
$24,49M | |
$0,75 | |
$80,92 | |
$0,36 | |
$0,43 | |
391,93M | |
662,41K | |
-- | |
$4,00 | |
$0,36 | |
-- | |
-- |
Heartbeam, Inc. (BEAT) is trading at $0,68 in after-hours trading as of 2026-10-05 21:17:00, up 56,47% ($0,25) from the regular-session close of $0,43.
After-hours trading shows how investors are pricing BEAT after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Heartbeam, Inc. (BEAT) moved from $0,38 to $0,67, representing a gain of 76,25% ($0,29).
The stock traded between $0,36 and $0,93 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 697,65 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8,6%
BEAT is currently trading at $0,67, placing it 8,6% of the way from its 52-week low of $0,36 to its 52-week high of $4,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Heartbeam, Inc. (BEAT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.